Merck Stock Rises on Strong Q2, But Estimates Fall

Merck's MRK stock has risen 5.6% in a month due to strong second-quarter 2026 performance, where the company beat estimates for both earnings and sales.

The key driver of this growth is the increased sales of oncology drugs, particularly Keytruda, which accounts for more than 55% of Merck's pharmaceutical sales and saw its sales rise 4% to $8.4 billion in the second quarter.

However, estimates have fallen significantly after the company raised its revenue outlook while lowering adjusted EPS guidance due to costs related to the Terns acquisition.

The decline in estimates has led some analysts to question whether to buy or sell the stock, highlighting the need to weigh Merck's key strengths against potential risks that could influence its future performance.